<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03624920</url>
  </required_header>
  <id_info>
    <org_study_id>THN102-202</org_study_id>
    <nct_id>NCT03624920</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime Sleepiness</brief_title>
  <official_title>Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime Sleepiness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theranexus</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theranexus</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, placebo-controlled, 3-way cross-over phase IIa trial comparing two dose
      levels of THN102 to placebo in patients suffering from Parkinson's disease associated with
      excessive daytime sleepiness.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The treatment duration is 2 weeks per period. Each treatment period is followed by a one-week
      washout period.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 12, 2018</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Actual">December 20, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Complete 3 way-Crossover</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Adverse events</measure>
    <time_frame>2 weeks</time_frame>
    <description>Number of participants with spontaneously reported treatment-related adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy in improving sleepiness (ESS)</measure>
    <time_frame>2 weeks</time_frame>
    <description>To quantify the efficacy of THN102 versus placebo in improving sleepiness as assessed. by the decrease of the total score (range 0-24) of the Epworth Sleepiness Scale (ESS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy Vigilance</measure>
    <time_frame>2 weeks</time_frame>
    <description>To quantify the efficacy of THN102 versus placebo in improving vigilance assessed by the Psychomotor Vigilance Test (PVT). The purpose of the PVT is to measure sustained attention, and give a numerical measure of improvement of vigilance by a decreased number of lapses in attention of the tested subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy Cognition</measure>
    <time_frame>2 weeks</time_frame>
    <description>To quantify the efficacy of THN102 versus placebo in improving cognition assessed by the Montreal Cognitive Assessment battery (MoCA). Possible maximum of 30 points. A final total score of 26 and above is considered normal.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Plasma concentrations at steady state</measure>
    <time_frame>2 weeks</time_frame>
    <description>To determine the trough plasma concentrations of modafinil and flecainide at steady state</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>THN102 Dosage A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>THN102 Dosage A is a Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>THN102 Dosage B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>THN102 Dosage B : 200 mg/2 mg THN102 is a combination of modafinil 100mg and flecainide 1 mg daily dosage is 200 mg of modafinil and 2 mg of flecainide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>THN102 Dosage C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>THN102 Dosage C : 200 mg/18 mg THN102 is a combination of modafinil 100mg and flecainide 9 mg daily dosage is 200 mg of modafinil and 18 mg of flecainide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>THN102 Dosage A</intervention_name>
    <description>THN102 Dosages A: placebo</description>
    <arm_group_label>THN102 Dosage A</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>THN102 Dosage B</intervention_name>
    <description>THN102 Dosage B : 200mg/2mg</description>
    <arm_group_label>THN102 Dosage B</arm_group_label>
    <other_name>Dosage B</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>THN102 Dosage C</intervention_name>
    <description>THN102 Dosage C: 200mg/18mg</description>
    <arm_group_label>THN102 Dosage C</arm_group_label>
    <other_name>Dosage C</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with a diagnosis of idiopathic Parkinson's disease as defined by the Movement
             Disorders Society (MDS).

          -  Subjects with Hoehn and Yahr scale score ≤ 4.

          -  Body mass index &gt; 18 kg/m2 and &lt; 35 kg/m2.

          -  Subjects should have a complaint of daytime sleepiness impacting their quality of life
             and/or daytime functioning (e.g. falling asleep while reading or watching television,
             while eating or talking with other people).

          -  Epworth Sleepiness Scale (ESS) score ≥ 14.

        Exclusion Criteria:

          -  Subjects with known or with a suspected sleep apnea syndrome or who have any other
             cause of excessive daytime sleepiness, such as shift work sleep disorder.

          -  Psychiatric and neurological disorders (other than Parkinson's disease),

          -  Cardiovascular disorders such as - but not limited to

          -  Uncontrolled moderate to severe hypertension

          -  History or current diagnosis of electrocardiogram (ECG) abnormalities indicating
             significant risk of safety for patients participating in the study

          -  Recent myocardial infarction

          -  Stable or unstable angina pectoris

          -  Cardiac insufficiency or history of heart failure

          -  Previous history of cardiac valvular surgery

          -  Subjects with current impulse control disorder.

          -  Subjects showing dementia or with MoCA &lt; 23.

          -  Subjects with current suicidal risk

          -  Current or recent (within one year) history of substance abuse or dependence disorder

          -  Other active clinically significant illness

          -  Subjects with hepatic or renal impairment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Christophe Corvol, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Hôpital La Pitié-Salpêtrière, 75651 Paris, France, Tel. +33 1 42 16 57 66, mail: jean-christophe.corvol@aphp.fr</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MGH Neurological Clinical Research Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>I. neurologická klinika Fakultní nemocnice u sv. Anny</name>
      <address>
        <city>Brno</city>
        <zip>65691</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologická klinika Fakultní nemocnice Hradec Králové</name>
      <address>
        <city>Hradec Králové</city>
        <zip>50005</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologická klinika Fakultní nemocnice Ostrava</name>
      <address>
        <city>Ostrava Poruba</city>
        <zip>70852</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut neuropsychiatrické péče</name>
      <address>
        <city>Praga 8</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologická klinika 1.LF UK a VFN v Praze</name>
      <address>
        <city>Praha 2</city>
        <zip>12821</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NEURO - Praha, s.r.o.</name>
      <address>
        <city>Praha 4</city>
        <zip>14000</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Axon Clinical, s.r.o.</name>
      <address>
        <city>Praha 5</city>
        <zip>15030</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologické oddělení Nemocnice Na Homolce</name>
      <address>
        <city>Praha 5</city>
        <zip>15030</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital NEurologique Pierre Wertheimer</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Hopital Salengro</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de la Timone Service de Neuro et pathologie du mouvement</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Guy de Chauliac</name>
      <address>
        <city>Montpellier</city>
        <zip>34195</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICM Centre d'Investigation Clinique Hôpital Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Purpan CIC Hall D 2eme etage</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Safavi, Neuroakademie Alzenau</name>
      <address>
        <city>Alzenau In Unterfranken</city>
        <zip>63755</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin, Klinik für Neurologie, Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologische Praxis Dipl. med. Christian Oehlwein</name>
      <address>
        <city>Gera</city>
        <zip>05551</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmakologisches Studienzentrum Chemnitz</name>
      <address>
        <city>Mittweida</city>
        <zip>09648</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Technische Universität München, Klinikum rechts der Isar, Neurologische Klinik und Poliklinik, Neuro-Kopf-Zentrum</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. med. Arnfin Bergmann</name>
      <address>
        <city>Neuburg</city>
        <zip>86633</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurozentrum Sophienstrasse</name>
      <address>
        <city>Stuttgart</city>
        <zip>70178</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NeuroPoint</name>
      <address>
        <city>Ulm</city>
        <zip>89073</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Dr. med. Joachim Springub / Wolfgang Schwarz, Studienzentrum Nord-West, *ausgelagerte Praxisräume:</name>
      <address>
        <city>Westerstede</city>
        <zip>26655</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nyírő Gyula Országos Pszichiátriai és Addiktológiai Intézet, Neurológiai Osztály</name>
      <address>
        <city>Budapest</city>
        <zip>1135</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Észak-Közép-budai Centrum</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Kenézy Gyula Egyetemi Kórház Neurológiai Osztály</name>
      <address>
        <city>Debrecen</city>
        <zip>4031</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Borsod-Abaúj-Zemplén Megyei Központi Kórház és Egyetemi Oktató Kórház, Stroke, Vascularis és Általános Neurológiai és Toxikológiai Osztály</name>
      <address>
        <city>Miskolc</city>
        <zip>3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PTE KK Neurológiai Klinika</name>
      <address>
        <city>Pécs</city>
        <zip>7623</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szegedi Tudományegyetem ÁOK Szent-Györgyi Albert Klinikai Központ Neurológiai Klinika</name>
      <address>
        <city>Szeged</city>
        <zip>6725</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Theranexus Investigational site</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>July 10, 2018</study_first_submitted>
  <study_first_submitted_qc>August 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2018</study_first_posted>
  <last_update_submitted>January 21, 2020</last_update_submitted>
  <last_update_submitted_qc>January 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Sleepiness</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

